International: Buyer announced for Nestle’s divested infant-nutrition licenses
Just days after it was announced that Nestle SA would agree to find a buyer for its licenses of infant formula as part of a deal to acquire Pfizer Inc., Aspen Pharmacare Holdings Ltd., based in South Africa, has struck a deal to buy the licenses that will allow the company to sell infant formula in Australia, South Africa and Namibia. Antitrust regulators in Australia have reportedly approved of the deal, while those in South Africa and Namibia are pending approval, according to Aspen. Aspen is the largest generic medicine producer in the Southern Hemisphere, supplying medicine to more than 150 countries. The move is part of a larger effort to expand businesses within Australia, Latin America and sub-Sahara Africa.
Full Content: Live Mint
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI